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Purpose: Most men with benign prostatic hyperplasia (BPH) have bothersome lower 
urinary tract symptoms (LUTS). This study aimed to investigate the safety and efficacy 
of high-performance system (HPS) laser photoselective vaporization of the prostate 
(PVP) for the treatment of BPH in men with detrusor underactivity (DU).
Materials and Methods: From March 2009, 371 patients with BPH were divided into 
2 groups according to the findings of preoperative urodynamic study: 239 (64.4%) pa-
tients with bladder outlet obstruction (BOO) and 132 (35.6%) patients with bladder out-
let obstruction with detrusor underactivity (BOO+DU). 120 W HPS laser PVP was per-
formed to resolve the BOO. The perioperative data and postoperative results at 1 month 
and 12 months, including the International Prostate Symptom Score (IPSS), maximum 
urinary flow (Qmax), and postvoid residual urine (PVR) values, were evaluated.
Results: Compared with the preoperative parameters, significant improvements in 
IPSS, Qmax, and PVR were observed in each group at 1 and 12 months after the 
operation. In addition, IPSS, Qmax, and PVR were not significantly different between 
the BOO and BOO+DU groups at 1 and 12 months after the operation. 
Conclusions: Surgery to relieve BOO in the patients with BPH seems to be an appro-
priate treatment modality regardless of the existence of DU. 
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INTRODUCTION
Bladder outlet obstruction (BOO) caused by benign pro-
static hyperplasia (BPH) is the most common cause of male 
lower urinary tract symptoms (LUTS) [1,2]. Among pa-
tients with BPH, some require surgery owing to the failure 
of medical treatment or complications such as acute uri-
nary retention, hematuria, and urinary stones. However, 
about 25% to 35% of patients report dissatisfaction with the 
results after transurethral resection of the prostate 
(TUR-P), despite the resolution of the BOO induced by BPH 
[3-5]. According to one study, there may be other causes of 
LUTS, such as a functional impairment of the bladder; 
moreover, men with BPH may have concomitant bladder 
dysfunction such as detrusor underactivity (DU) [6]. There 
have been some studies about the effect of surgery such as 
TUR-P in men with BPH and DU; however, it remains con-
troversial whether elimination of BOO improves LUTS or 
not.
Urodynamic study is an optional diagnostic modality in 
patients with BPH. Therefore, it was done in selected pa-
tients whose LUTS was suspected to be induced by prob-
lems other than BPH. However, men with BPH may have 
other concomitant abnormalities that influence bladder 
function. Generally, most men with BPH are older adults; 
therefore, they also have comorbidities, like diabetes, that 
influence bladder function. Also, bladder function in older 
adults can be altered by aging itself. As a result, LUTS in Korean J Urol 2011;52:824-828
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FIG. 1. Distribution of patients according to the Schäfer nomo-
gram. The number of patients who showed weak (+) contractility 
was 92, the number who showed weak (-) contractility was 32, 
and the number who showed very weak contractility was 8. The 
patient group with detrusor underactivity included 132 pati-
ents.
these men can be induced by mixed etiologies rather than 
BPH alone. Therefore, if we get information about bladder 
function as well as the degree of BOO through preoperative 
urodynamic study, it would be a great help in selecting good 
candidates for surgery as well as in predicting post-
operative outcomes.
Recently, there have been many reports about the effect 
of laser surgery for BPH. This procedure shows similar ef-
fects and patient satisfaction with conventional TUR-P 
and, in addition, may have several advantages compared 
with TUR-P. Retrograde ejaculation and urethral stricture 
are reported to be lower than with TUR-P. Particularly, the 
120 W high-performance system (HPS) laser has been re-
garded as an effective and safe procedure among the vari-
ous types of laser surgery for BPH [7-10].
Therefore, we evaluated the short- and long-term out-
comes according to the degree of detrusor contractility by 
preoperative urodynamic study in patients with BPH after 
120 W HPS laser surgery.
MATERIALS AND METHODS
The subjects were patients who were diagnosed as having 
BPH, who underwent 120 W Greenlight HPS laser photo-
selective vaporization of the prostate (PVP) from March 
2009, and who were available for follow-up for up to 12 
months after surgery. History taking, physical examina-
tion, prostate-specific antigen (PSA) measurement, trans-
rectal ultrasonography, the International Prostate Symp-
tom Score (IPSS) questionnaire, and urodynamic study 
were performed in all patients. Patients with a history of 
neurogenic bladder, prostate cancer, or urethral stricture 
were excluded. 
Pressure-flow study (PFS) was performed on the pa-
tients, and the degree of BOO and the contractility of the 
detrusor muscle were assessed by use of the Schäfer 
nomogram. Patients maintained alpha-blocker medi-
cation during PFS and uroflowmetry. According to the re-
sults of the PFS, the patients were divided into two groups: 
the group with BOO only (BOO group) and the group with 
BOO with DU (BOO+DU group). We defined DU as pa-
tients whose contractility was lower than weak by the 
Schäfer nomogram.
Indications for operation were persistent symptoms 
even after the administration of alpha-blockers or the com-
bination of alpha-blockers and 5 alpha reductase inhibitors 
for longer than 3 months and cases in which medications 
were avoided because of the side effects.
General or spinal anesthesia was used, and the surgery 
was performed by a single surgeon. A continuous irrigation 
system 22 Fr resectoscope with a 30 degree lens and a 75 
degree laser fiber was used. All prostate tissue causing ob-
struction was removed until a fine surgical cavity was 
formed, as in TURP. An 18 Fr urethral catheter was placed 
after the operation and was removed the next day, taking 
into consideration the degree of hematuria.
Operation time, the energy used during the operation, 
the catheter indwelling period, and the hospitalization pe-
riod were analyzed. The outcomes and effectiveness of sur-
gery at 1 month and 12 months after surgery were com-
pared with preoperative values by assessing the IPSS, 
maximal flow rate (Qmax), and postvoid residual urine vol-
ume (PVR).
1. Statistical analysis
Postoperative Qmax, PVR, and IPSS with quality of life 
(QoL) score were obtained at 1 and 12 months after surgery. 
Operation time, amount of applied energy, and duration of 
catheterization were assessed. SPSS ver. 18.0 (SPSS Inc., 
Chicago, IL, USA) was used for statistical analysis. Posto-
perative Qmax, PVR, IPSS, and QoL score were compared 
with preoperative values by using the t-test; p-values of 
less than 0.05 were defined as significant.
RESULTS
A total of 371 patients were selected. The mean age of the 
patients was 69.3±8.6 years.
The patient group with only BOO included 239 cases 
(64.4%), and the patient group with BOO+DU included 132 
patients (35.6%). Patient distribution of DU was analyzed 
according to the Schäfer nomogram as weak+, weak-, and 
very weak. The number of patients in the weak+ group was 
92, that in the weak- group was 32, and that in the very 
weak group was 8 (Fig. 1).
The patients’ preoperative clinical characteristics, such 
as age, prostate volume, PSA level, and IPSS, were com-
pared, and there were no significant differences between 
the two groups. In addition, there were no statistically sig-
nificant differences in the Qmax or PVR between these two 
groups (Table 1). There were no significant differences in 
operation time, lasing time, total laser energy, or post-
operative urinary catheter indwelling time between these Korean J Urol 2011;52:824-828
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TABLE 1. Preoperative clinical findings
　 BOO BOO+DU
No. of patients (%)
Age (mean±SD)
Prostate volume (mean±SD)
PSA (mean±SD)
IPSS (Total)
IPSS (Voiding)
IPSS (Storage)
QoL
Qmax (ml/sec)
PVR (ml)
Maximal capacity (ml)
Pdet at Qmax (cmH2O)
MUCP (cmH2O)
239 (64.4)
68.7±7.3
  46.8±16.8
    4.0±4.41
20.35±9.15
12.17±5.01
  8.27±4.55
  4.28±1.15
10.1±5.7
  102.35±100.51
  427.8±105.4
26.6±8.4
  79.3±27.1
132 (35.6)
71.18±7.87
  42.19±18.96
  4.18±4.17
20.42±8.78
12.05±5.15
  9.26±3.51
  4.26±0.99
  8.71±5.15
  117.33±101.51
  448.3±135.6
28.3±6.7
  76.1±25.9
BOO: bladder outlet obstruction, DU: detrusor underactivity, 
PSA: prostate-specific antigen, IPSS: International Prostate 
Symptom Score, QoL: quality of life, Qmax: maximum urinary 
flow, PVR: postvoid residual urine, MUCP: maximum urethral 
closure pressure
TABLE 2. Perioperative results
　 BOO BOO+DU
Duration of surgery 
(min)
Lasing time (min)
Total laser energy 
(J)
Duration of cathe-
terization (d)
  40.4±33.1
  20.7±12.2
  154,293.9±213,421.5
  0.83±0.35
41.5±35.4
19.9±11.8
160,121±204,985.3
0.86±0.41
BOO: bladder outlet obstruction, DU: detrusor underactivity
TABLE 3. Changes in the IPSS after the operation in the BOO and BOO+DU groups
BOO BOO+DU
Scores
IPSS Total
IPSS Voiding
IPSS Storage
QoL
Preoperative
20.35±9.51
12.17±5.01
  8.27±4.55
  4.28±1.15
1 mo
9.92±7.16
a
6.64±6.16
a
4.31±3.06
a
  2.0±1.13
a
12 mo
10.11±9.61
a
  5.43±5.44
a
  4.89±3.41
a
2.07±1.5
a
Preoperative
20.42±8.78
12.05±5.15
  9.26±3.51
  4.26±0.99
1 mo
10.63±8.47
b
7.22±5.6
b
  5.17±3.76
b
  2.77±1.41
b
12 mo
10.88±7.87
b
  5.48±3.81
b
  4.97±4.33
b
  3.09±1.61
b
BOO: bladder outlet obstruction, DU: detrusor underactivity, IPSS: International Prostate Symptom Score, QoL: quality of life, 
a: p
＜0.05 compared with preoperative data in BOO group, 
b: p＜0.05 compared with preoperative data in BOO+DU group
two groups (Table 2).
One month after the operation, the total IPSS of the BOO 
group was significantly improved from 20.35±9.15 points 
to 9.92±7.16 points. The voiding symptom score was sig-
nificantly improved from 12.17±5.01 points to 6.64±6.16 
points, and the storage symptom score was improved from 
8.27±4.55 points to 4.31±3.06 points at 1 month after the 
operation. All changes were significant (p＜0.05).
The total IPSS of the BOO+DU group was significantly 
improved from 20.42±8.78 to 10.63±8.47, and the voiding 
symptom score was significantly improved from 12.05± 
5.15 to 7.22±5.60. The storage symptom score was sig-
nificantly improved from 9.26±3.51 to 5.17±3.76 at 1 
month after the operation (p＜0.05).
One month after the operation, the QoL score in the BOO 
group was significantly improved from 4.28±1.15 to 2.00± 
1.13, and in the BOO+DU group, the QoL score was sig-
nificantly improved from 4.26±0.99 to 2.77±1.41 (p＜0.05).
In the BOO group, compared with preoperative data, the 
postoperative 1 month Qmax was improved from 10.1±5.7 
ml/s to 15.3±9.05 ml/s and PVR was improved from 102.35± 
100.51 ml to 23.08±21.61 ml. In the BOO+DU group, post-
operative 1 month Qmax was improved from 8.71±5.15 
ml/s to 13.35±7.80 ml/s, and PVR was improved from 
117.33±101.51 ml to 30.01±40.34 ml. All changes were sig-
nificant (p＜0.05).
At 12 months after the operation, in the BOO group, total 
IPSS, voiding symptom score, storage symptom score, QoL 
score, Qmax, and PVR showed significant improvement 
compared with preoperative data (p＜0.05). In the BOO+ 
DU group at 12 months after the operation, total IPSS, 
voiding symptom score, storage symptom score, QoL score, 
Qmax, and PVR showed significant improvement com-
pared with preoperative data (p＜0.05).
There were no significant differences between the BOO 
and BOO+DU groups at the same time interval period after 
the operation (postoperative 1 and 12 months (Tables 3, 4).
There were no severe postoperative complications that 
required re-hospitalization or re-do operation for gross 
hematuria, retrograde ejaculation, urethral stricture, or 
urinary tract infection. Acute urinary retention was ob-
served in a total of 27 patients (7%): 14 cases in the BOO 
group and 13 cases in the BOO+DU group. In all cases, only 
temporary urinary catheterization for 2 weeks was needed. 
After the catheter was removed, the patients were all able 
to void well. A total of 48 cases (13%) of mild dysuria were 
observed: 21 cases in the BOO group and 27 cases in the 
BOO+DU group. In all cases, the symptoms were managed 
by follow-up or conservative care such as temporary an-
algesic medications.
DISCUSSION
In the patients with BOO associated with impaired de-
trusor contractility, it is still controversial whether elimi-Korean J Urol 2011;52:824-828
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TABLE 4. Changes in Qmax and PVR after the operation 
　 Preoperative 1 mo 12 mo
BOO
    Qmax (ml/s)
    PVR (ml)
BOO+DU
    Qmax (ml/s)
    PVR (ml)
10.1
102.35
    8.71
117.33
15.3
23.08
13.35
30.01
15.53
33.41
13.94
22.08
Qmax: maximum urinary flow, PVR: postvoid residual urine, 
BOO: bladder outlet obstruction, DU: detrusor underactivity
nating BOO improves LUTS. But, according to our results, 
patients with BOO and DU showed improvements in pre-
operative LUTS and were satisfied about their post-
operative results after relief of BOO by the 120 W HPS 
laser. 
BPH is the major cause of male LUTS, and the symptoms 
in many patients with BPH are related to BOO induced by 
enlargement of the prostate. However, BOO may not devel-
op in all patients with BPH, and LUTS in some patients 
with BPH are associated with not only BOO but also blad-
der function. Some investigators reported that BOO is ob-
served in about 50% to 70% of males with BPH; moreover, 
37% to 47% of patients with BPH also have bladder dys-
function such as impaired detrusor contractility as well as 
BOO [6,11]. Several factors influence bladder function. 
Impaired detrusor contractility can be induced by BOO it-
self, because alteration of bladder function can appear as 
a secondary change following BOO. In addition, hormonal 
changes, aging, concomitant disease, and neurologic dis-
orders can affect bladder function and lead to impairment 
of detrusor contractility [5]. Most patients with BPH are 
of old age, and aging is one of the factors that affect bladder 
function. Moreover, the incidence of a lower testosterone 
level and diseases such as diabetes or stroke increase in 
males with old age. These are among the factors that affect 
bladder function. As a result, LUTS in several patients 
with BPH may be related to both BOO and functional im-
pairment of the bladder. Similar to previous reports, we al-
so observed that 35.6% of BPH patients who needed surgi-
cal treatment showed BOO and DU in this study. There-
fore, assessment of detrusor function as well as BOO in men 
with LUTS induced by BPH is important for selecting a 
treatment strategy and, in addition, may help to predict 
which patients need additional medications after relieving 
BOO [12]. 
There have been several studies about the usefulness of 
preoperative urodynamic study. Abrams et al reported 
that the success rate of the operation was approximately 
72% when urologists select surgical candidates according 
to Qmax only [13]. However, the success rate of surgery rose 
to 88% when the candidates for surgery were selected by 
the results of urodynamic evaluation including PFS. This 
higher success rate after surgery suggested that it is possi-
ble to diagnose the patients who have true BOO. In such 
a manner, urodynamic study is a helpful method for evalu-
ating patients with BOO. Thus, urodynamic study could be 
of great help in the selection of patients before surgery and 
in the prediction of postsurgical prognosis [12,14,15].
Because of deterioration of bladder emptying, DU leads 
to a decreased flow rate and higher PVR. Therefore, it was 
thought that men with BOO and DU would have greater 
PVR and a higher IPSS as well as lower flow rates compared 
with those without DU [16,17]. However, in this study, only 
a small difference was observed in Qmax and PVR between 
the BOO only and BOO+DU groups preoperatively, and the 
difference was not significant. We supposed that this result 
was related with voiding by abdominal straining in the pa-
tients in the BOO+DU group, because an elevation in ab-
dominal pressure was noted in most of the patients in the 
BOO+DU group during PFS. In addition, the severity of DU 
might be mild compared with that in other previous 
studies.
The effect of surgery in BPH patients with BOO and DU 
is still controversial. DU is one of the important factors that 
influences the prognosis of BPH treatment and is found in 
approximately 20% to 25% of males with LUTS. Thomas 
et al reported in a study conducted on patients with DU that 
deterioration of detrusor muscle contractility is the major 
cause of persistent symptoms after surgery [14]. Thus, DU 
has been considered to be a risk factor that predicts poor 
prognosis even after surgery in patients with BPH [18,19]. 
There were reports that LUTS can be improved by elimi-
nating BOO through transurethral surgery or photoselec-
tive vaporization of the prostate in patients with BPH with-
out postoperative alterations of detrusor contractility 
[15,20]. In addition, Monoski et al reported that even in 
BPH patients with impaired detrusor contractility and a 
preoperative history of urinary retention, eliminating 
BOO by KTP laser improves both subjective and objective 
parameters [21]. Park et al reported that there were sig-
nificant improvements in Qmax, voiding urine volume, 
PVR, IPSS, and QoL scores at 6 months after PVP treat-
ment [22]. In our study, similarly, in the BOO with DU 
group, 1 month after 120 W HPS laser operation, IPSS 
scores, QoL, Qmax, and PVR were improved and the im-
provements were maintained for 12 months. During the 
follow-up period, in the BOO with DU group, cholinergic 
medication was able to be reduced to less than preoperative 
doses or stopped altogether after the operation in almost 
all patients. In this study, most of the men with BOO in-
duced by BPH benefited from 120 W HPS laser with an im-
provement in both subjective and objective voiding param-
eters regardless of the presence of DU. 
Additionally, further evaluation is necessary about the 
effect of concomitant DU on outcomes after BPH surgery 
because bladder function can deteriorate as patients grow 
older. As a result, more long-term follow-up is needed to 
evaluate the changes in LUTS in patients with BOO and 
DU.Korean J Urol 2011;52:824-828
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CONCLUSIONS
Our results suggest that relieving BOO may improve the 
LUTS and QoL in BPH patients with BOO and DU as well 
as in patients without DU. Therefore, surgery to relieve 
BOO in patients with BPH seems to be an appropriate 
treatment modality regardless of the existence of DU. 
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